文献速递肺外科

辅助化疗未给非典型类癌患者带来生存优势

Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors.
PubMed 文献 · Ann Thorac Surg · 2017-07-29

该研究基于美国国家癌症数据库2006至2011年数据,纳入581例接受肺叶或全肺切除的非典型类癌患者,采用倾向性评分和生存分析评估辅助化疗与pN+及pN0患者的生存关联。结果显示,pN+和pN0患者接受辅助化疗均未获得生存优势,需进一步研究明确化疗的合理使用。

要点

  • pN+非典型类癌患者辅助化疗未显示生存获益(p=0.46)。
  • pN0患者辅助化疗亦无生存优势(p=0.54)。
  • 需进一步研究明确非典型类癌术后化疗的适用人群。

核心结论

  • 在国家级分析中,pN+和pN0非典型类癌患者术后辅助化疗均未带来生存优势。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2006至2011年数据,纳入581例接受肺叶或全肺切除的成人非典型类癌患者,采用4:1最近邻倾向性评分和生存分析。

主要发现

  • 581例中363例(62.5%)为pN0,218例(37.5%)为pN+。
  • pN0患者中15例(4.1%)接受辅助化疗,pN+患者中89例(40.8%)接受辅助化疗。
  • pN+患者未调整12个月和60个月生存率:辅助化疗组98.9%和47.9%,单纯手术组98.4%和67.1%,p=0.46。
  • 倾向性匹配后pN0患者12个月和60个月生存率:辅助化疗组86.7%和73.3%,单纯手术组87.9%和72.3%,p=0.54。

临床怎么用

  • 对于pN+或pN0非典型类癌患者,术后辅助化疗不应常规推荐以追求生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the use of adjuvant chemotherapy in patients with pathologically node-positive (pN+) atypical carcinoid tumor of the lung is an accepted practice, controversy exists about its use in pathologically node-negative (pN0) patients. Our aim was to determine whether a survival advantage exists in patients receiving chemotherapy postoperatively for pN0 or pN+ atypical carcinoid tumors of the lung. METHODS: Adult patients treated with lobectomy or pneumonectomy for pulmonary atypical carcinoid tumor were identified using the National Cancer Data Base, 2006 to 2011. Propensity scoring (4:1 nearest neighbor algorithm) and survival analysis were used to examine the association between adjuvant chemotherapy and pN+ versus pN0 atypical carcinoid tumors. RESULTS: Of the total 581 patients identified with a diagnosis of atypical carcinoid of the lung, 363 (62.5%) were found to be node negative at the time of operation and 218 (37.5%) had node-positive disease. Adjuvant chemotherapy was used in 15 patients (4.1%) with pN0 disease and 89 patients (40.8%) with pN+ disease. Unadjusted survival, at 12 and 60 months, was similar between pN+ patients who were treated with adjuvant chemotherapy versus patients who received operation alone (adjuvant chemotherapy: 98.9% at 12 months and 47.9% at 60 months versus operation alone: 98.4% and 12 months and 67.1% at 60 months, p = 0.46) and for propensity-matched pN0 (adjuvant chemotherapy: 86.7% at 12 months and 73.3% at 60 months versus operation alone: 87.9% at 12 months and 72.3% at 60 months, p = 0.54). CONCLUSIONS: In a national-level analysis, the use of adjuvant chemotherapy postoperatively in patients with pN+ and pN0 disease conferred no survival advantage; further study is needed to determine proper chemotherapy use for these patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Anderson KL, Mulvihill MS, Speicher PJ, et al. Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann Thorac Surg. 2017. PMID: 28760471. doi:10.1016/j.athoracsur.2017.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。